复星医药(02196.HK)：芦沃美替尼片新适应症上市申请获受理并纳入优先审评

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., has received acceptance for the drug application of Fumainin® (generic name: Luwomeitini tablets) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with Neurofibromatosis type 1 (NF1), which has been included in the priority review process by the National Medical Products Administration [1] Group 1 - The drug Fumainin® is developed for a new indication targeting adult patients with NF1 [1] - The application for the drug has been accepted by the National Medical Products Administration [1] - The drug has been included in the priority review process, indicating its potential significance in the market [1]